Results 91 to 100 of about 24,524 (277)
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan +5 more
wiley +1 more source
, 2016 Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X +4 more
core
Identification of antitumor sulfonylurea binding proteins of HeLa plasma membranes
, 1995 Plasma membranes of cultured HeLa S cells bound the tritiated antitumor sulfonylurea [3H]LY181984 with high affinity (Kd of about 25 nM). The number of binding sites, estimated to represent 30 to 35 pmol/mg protein, would represent a low abundance ...
Lawrence, James +4 more
core +1 more source
Solvent Free Synthesis and Safener Activity of Sulfonylurea Benzothiazolines
, 2017 A series of novel sulfonylurea benzothiazoline were designed by splicing active groups and bioisosterism. A solvent-free synthetic route was developed for the sulfonylurea benzothiazoline derivatives via the cyclization and carbamylation.
Fei Ye +6 more
core +2 more sources
FunctionNeuronal activity and energy supply must maintain a fine balance for neuronal fitness. Various channels of communication between the two could impact network output in different ways.
Sonal Kedia +3 more
doaj +1 more source
Sulfonylureas in type 2 diabetes mellitus: Current evidence, conflicts and clinical implications
Nigerian Journal of Medicine, 2017 INTRODUCTION: We sought to explore the current state of evidence on sulfonylurea therapy in type 2 diabetes mellitus (T2DM) and critically examine the recommendations of major practice guidelines,and the overall ramifications of the issues thereof in ...
Chiedozie Kenneth Ugwoke +3 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Introduction Pharmacokinetic data suggest a potential dose‐dependent effect of sodium–glucose co‐transporter‐2 (SGLT‐2) inhibitors on surrogate markers of efficacy, but the impact of SGLT‐2 inhibitor dose on renal and cardiovascular outcomes remains uncertain.
Elias John Elenjickal +5 more
wiley +1 more source
Chronicle of Diabetes Research and PracticeIntroduction: The present study evaluated the bioequivalence of a fixed-dose combination (FDC) of sitagliptin and glimepiride with the originator reference product.
Prashant Kumthekar +4 more
doaj +1 more source
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano +4 more
wiley +1 more source